Financing ·
Autolus Therapeutics plc entered into a Note Purchase Agreement with Perceptive Credit Holdings V, LP on July 30…
AUTLAutolus Therapeutics plc
Autolus Therapeutics plc entered into a Note Purchase Agreement with Perceptive Credit Holdings V, LP on July 30, 2026, establishing a senior secured notes facility with an aggregate principal amount of up to $250.0 million. The company issued the first tranche of notes totaling $75.0 million, with additional tranches available subject to revenue milestones and timing constraints through January 2030. The facility matures on July 30, 2031, accrues interest based on SOFR plus a margin between 6.75% and 7.25%, and requires the maintenance of minimum liquidity and consolidated net revenue covenants. Concurrently, Autolus issued warrants to purchase up to 3,500,000 American Depositary Shares at an exercise price of $1.9314 per share, with additional warrants issuable upon future tranches. The company operates in the biotechnology industry, specializing in the development of CAR T-cell therapies for cancer treatment.